Perspective Therapeutics’ (CATX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

A number of other equities analysts also recently commented on CATX. Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, March 27th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective for the company. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Price Performance

CATX opened at $2.05 on Monday. The company’s 50 day simple moving average is $2.85 and its two-hundred day simple moving average is $6.07. Perspective Therapeutics has a 1-year low of $1.90 and a 1-year high of $19.05.

Insider Buying and Selling

In other news, CFO Juan Graham bought 33,333 shares of the company’s stock in a transaction on Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. The trade was a 1,649.33 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This represents a 45.62 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 115,696 shares of company stock valued at $256,344. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. FMR LLC boosted its position in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Millennium Management LLC acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at $4,132,000. State Street Corp boosted its holdings in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the period. Octagon Capital Advisors LP grew its stake in Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares in the last quarter. Finally, Affinity Asset Advisors LLC increased its holdings in Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.